RXi Says Initial Rx Focus Will Be Anti-Scarring, Retinal Disorders

These core areas "represent opportunities where RXi has the ability to take products into the clinic and through proof of concept," and the firm expects the anti-scarring effort to yield an investigational new drug application by the end of next year.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories